Navigation Links
Weight-loss surgery can reduce liver damage
Date:5/4/2014

Chicago, IL (May 4, 2014) Bariatric surgery, which is best known for its ability to help patients lose substantial weight, can also result in significant improvement in nonalcoholic fatty liver disease (NAFLD), according to new research presented today at Digestive Disease Week (DDW). Researchers at the University of South Florida-Tampa found that bariatric surgery resolved liver inflammation and reversed early-stage liver fibrosis, the thickening and scarring of liver tissue, by reducing fat deposits in the liver.

"About 30 percent of the U.S. population suffers from this disease, which is increasing, and more than half are also severely obese," said Michel Murr, MD, lead researcher of the study, professor of surgery and director of Tampa General Hospital and USF Health Bariatric Center. "Our findings suggest that providers should consider bariatric surgery as the treatment of choice for nonalcoholic fatty liver disease in severely obese patients."

Dr. Murr and his colleagues suggest that bariatric surgery be considered for patients with a body mass index greater than 35 and obesity-related co-morbidities, or a body mass index of greater than 40. They note that traditional interventions, such as medications, have a low success rate with these patients.

Researchers compared liver biopsies from 152 patients one at the time of the bariatric procedure and a second an average of 29 months afterwards. In examining pre-operative biopsies, researchers identified patients with cellular-level manifestations of nonalcoholic fatty liver disease, specifically, fat deposits and inflammation of the liver. These types of liver damage can lead to liver fibrosis and cirrhosis, which can be life-threatening.

After reviewing post-operative biopsies, they found that bariatric surgery resulted in improvements for these patients. In the post-operative biopsies, researchers found that fat deposits on the liver resolved in 70 percent of patients. Inflammation was also improved, with lobular inflammation resolved in 74 percent of patients, chronic portal inflammation resolved in 32 percent, and steatohepatitis resolved in 88 percent.

In addition to these improvements, 62 percent of patients with stage two liver fibrosis had an improvement or resolution of the fibrosis. One of three patients with cirrhosis also showed improvement. Dr. Murr noted that these findings on fibrosis reversal apply only to early-stage fibrosis, and not late-stage liver disease.

"We are in the midst of an obesity epidemic that can lead to an epidemic of nonalcoholic fatty liver disease," said Dr. Murr. "As a tool in fighting obesity, bariatric surgery could also help prevent the emergence of widespread liver disease."

Dr. Michel Murr will present data from the study "Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis," abstract 233, on Sunday, May 4, at 8:30 a.m. CT, in room S504BCD of McCormick Place. For more information about featured studies, as well as a schedule of availability for featured researchers, please visit http://www.ddw.org/press.


'/>"/>

Contact: Aimee Frank
newsroom@gastro.org
301-941-2620
Digestive Disease Week
Source:Eurekalert

Related medicine news :

1. Slim pickings for 2 weight-loss drugs?
2. The Federal Trade Commission Files Lawsuit Seeking an Injunction Against Marketer of Weight-loss Products Over Alleged False Advertising, Parker Waichman LLP Reports
3. Medicare Center of Excellence Policy may limit minority access to weight-loss surgery
4. San Jose Woman Turns Life Around After Weight-Loss Surgery
5. Man’s Big Weight-Loss Plan Tailored With Skinny Limit’s Help
6. Weight-Loss Surgery May Help Moderately Obese, Too
7. Womens Weight-Loss Surgery May Benefit Later Offspring
8. SENSA® Weight-Loss System Now Available at Defense Commissary Agency Locations Nationwide
9. Beyond Rules—Sean A. Anderson’s Remarkable 275 Pound Weight-Loss Approach Now on Paperback and E-book
10. Gene Test May Help Predict Success of Weight-Loss Surgery
11. Study Supports Broader Access to Lap-Band Weight-Loss Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: